dev-novonordisk-pcp-academy.kundentestserver.com Open in urlscan Pro
89.110.140.22  Public Scan

Form analysis
0 forms found in the DOM

Text Content

100% Created with Snap
 * 00 Introduction
 * 01 Opportunity
 * 02 Dynamics
 * 03 Activation
 * 03 Expansion plan
 * 04 Finish

Browse the Chapters

 * 01
   Opportunity
   Understand the primary care opportunity
   
   * Expansion opportunity and long-term primary care physician strategy
 * 02
   Dynamics
   Immerse into primary care
   
   * Primary care in healthcare systems
   * Primary care market dynamics
   * Primary care physician mindset
 * 03
   Activation
   Build your own expansion plan
   
   * Expansion segments
   * Build local expansion plan
     * 01. Understand local primary care landscape
     * 02. Identify primary care expansion approach
     * 03. Localise primary care expansion strategy
     * Public affairs Establish strong primary healthcare systems that provide
       early and effective treatment of diabetes
     * Medical Identify and empower the local environment to engage with PCPs
       and educate on type 2 diabetes and GLP-1
     * Marketing Drive PCP readiness and activation for prescribing oral GLP-1
       in early-stage patients
     * Commercial Execute on a focused go-to-market approach for moving into
       expansion segments
     * 04. Build cross-functional activation plan



Explore the undiscovered

Introduction

How to explore





 * YOUR GUIDE TO
   THE PORTAL
   
    * 
   
    * The primary care activation portal will assist you in expanding to MOAD
      writing primary care physicians – it is a one stop shop for any guidance
      that you need on how to build your local primary care activation plan .
   
    * 
   
    * The portal contains three sections: Opportunity, Dynamics, and Activation,
      covering the primary care opportunity, primary care market insights,
      relevant expansion segments, and the primary care strategy. Templates,
      tools, and relevant links will be available as part of each section.
   
    * 
   
    * The portal is targeted at cross-functional affiliate teams (e.g., product
      managers etc.) .


 * CONTACT FOR YOUR
   JOURNEY
   
   If you have any questions or comments about the portal, or would like to
   discuss on specific expansion scenarios in your country, please reach out to:
   
    * 
   
    * Fahad Nadeem Khan
      
      fnak@novonordisk.com

“ We are very excited to kick-off our strategies and programs on how we intend
to win with Rybelsus® in primary care.

Rybelsus® represents Novo Nordisk largest opportunity for expanding and winning
in primary care where over 80% of current modern oral antidiabetics are
initiated – although we, in many markets, do have an established footprint with
primary care already – the journey to establish Novo Nordisk as a serious player
in primary care starts now! We hope you will find the insights and resources on
this platform to build a solid foundation for expansion in primary care, also
paving the way for our future primary care assets.“

– Camilla Olsen, VP Rybelsus® Marketing





READY TO START?

In this travel guide you will find everything you need for your trip to the
Primary Care Universe.

 * 01
   
   Opportunity
   
   A new and exciting universe is waiting for us! Learn about the significant
   opportunities.
   
   Let's go
   
   

 * 02
   
   Dynamics
   
   A new and undiscovered physician group is waiting for us! Learn about their
   treatment mindset and behaviours.
   
   Let's go
   
   

 * 03
   
   Activation
   
   A new way of driving activation is required. Learn about the cross-functional
   strategy needed to activate the primary care physicians.
   
   Let's go
   
   




FRANCE JAPAN UK 1 2 3 Download PCP Resource Centre PROS CONS NN market research
findings Refer to launch guide in ‘How’ section for more details Refer to
primary care mapping guidance in ‘How’ section for more details Refer to primary
care mapping guidance in ‘How’ section for more details on strategies employed
by other countries 31% HbA1c REDUCTION AVOIDING INJECTABLES 18% SAFETY PROFILE
12% 29% HbA1c REDUCTION CV RISK REDUCTION 14% SAFETY PROFILE 11% YOUR RESULT: NN
market research findings